Metabolex raises $32M in fourth round

Hayward, CA-based Metabolex has raised $32 million in a Series D financing and plans to use the money to accelerate clinical testing of MBX-8025, a treatment for dyslipidemia. Additionally, the company will further the development of several preclinical programs. The round was led by MPM BioEquities and included contributions from new investors AllianceBernstein, Deerfield Management and T. Rowe Price as well as existing investors. Last year, Johnson & Johnson bought into Metabolex's program for diabetes and other metabolic conditions in a rich collaboration pact. Metabolex has two diabetes drugs in development along with programs in obesity and blood fat disorders.

- see the release on the round

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.